Literature DB >> 3571937

The effect of prostaglandins, branched-chain amino acids and other drugs on the outcome of experimental acute porcine hepatic failure.

M H Alp, R Hickman.   

Abstract

Prostaglandins, N-acetyl-cysteine, cholestyramine and essential phospholipids have all been shown to protect experimental animals from severe hepatic damage in various models when used prophylactically. Silibinin has been used in the treatment of Amanita phalloides poisoning. Branched-chain amino acids have been recommended in acute hepatic failure. We have used all these forms of therapy at the time of initiation of hepatic failure in a reliable pig model. Of the above, only prostaglandins have been shown to reverse the effects of the hepatic insult in terms of prolonged survival and histological changes. Although conventional liver function tests and plasma amino acids in prostaglandin-treated animals are not improved, cerebrospinal fluid amino acids remain normal, in contrast to the other groups of untreated and treated hepatic failure animals.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3571937     DOI: 10.1016/s0168-8278(87)80016-8

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  8 in total

Review 1.  Animal models of fulminant hepatic failure.

Authors:  J Terblanche; R Hickman
Journal:  Dig Dis Sci       Date:  1991-06       Impact factor: 3.199

2.  Combination adjuvant chemotherapy with oxaliplatin, 5-fluorouracil and leucovorin after liver transplantation for hepatocellular carcinoma: a preliminary open-label study.

Authors:  Qing Zhang; Hong Chen; Qin Li; Yunjin Zang; Xinguo Chen; Weilong Zou; Letian Wang; Zhong-Yang Shen
Journal:  Invest New Drugs       Date:  2011-08-02       Impact factor: 3.850

Review 3.  Fulminant hepatitis.

Authors:  S Sinclair; A Wakefield; G Levy
Journal:  Springer Semin Immunopathol       Date:  1990

4.  Prostacyclin inhibition by indomethacin aggravates hepatic damage and encephalopathy in rats with thioacetamide-induced fulminant hepatic failure.

Authors:  Chi-Jen Chu; Ching-Chin Hsiao; Teh-Fang Wang; Cho-Yu Chan; Fa-Yauh Lee; Full-Young Chang; Yi-Chou Chen; Hui-Chun Huang; Sun-Sang Wang; Shou-Dong Lee
Journal:  World J Gastroenterol       Date:  2005-01-14       Impact factor: 5.742

5.  Treatment of fulminant viral hepatic failure with prostaglandin E. A preliminary report.

Authors:  S B Sinclair; G A Levy
Journal:  Dig Dis Sci       Date:  1991-06       Impact factor: 3.199

6.  Biochemical and clinical response of fulminant viral hepatitis to administration of prostaglandin E. A preliminary report.

Authors:  S B Sinclair; P D Greig; L M Blendis; M Abecassis; E A Roberts; M J Phillips; R Cameron; G A Levy
Journal:  J Clin Invest       Date:  1989-10       Impact factor: 14.808

7.  Preclinical models of acute liver failure: a comprehensive review.

Authors:  Joshua Hefler; Braulio A Marfil-Garza; Rena L Pawlick; Darren H Freed; Constantine J Karvellas; David L Bigam; A M James Shapiro
Journal:  PeerJ       Date:  2021-12-09       Impact factor: 2.984

Review 8.  Liver cytoprotection by prostaglandins.

Authors:  J Quiroga; J Prieto
Journal:  Pharmacol Ther       Date:  1993       Impact factor: 12.310

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.